human
rhinovirus
hrv
respons
half
case
common
cold
cost
billion
usd
annual
medic
visit
miss
school
work
assess
made
antivir
activ
mechan
action
paeonol
pa
pgg
paeonia
lactiflora
root
toward
cell
use
tetrazolium
method
realtim
quantit
revers
transcript
polymeras
chain
reaction
enzymelink
immunosorb
assay
result
compar
refer
control
ribavirin
base
inhibitori
concentr
valu
pgg
time
activ
toward
cell
respect
ribavirin
constitu
rel
high
select
index
valu
pa
pgg
interact
particl
constitu
inhibit
infect
ad
viru
inocul
h
adsorpt
period
hrv
h
later
moreov
rna
replic
level
hrv
remark
reduc
cultur
treat
constitu
find
suggest
pgg
pa
may
block
reduc
entri
virus
cell
protect
cell
viru
destruct
abat
viru
replic
may
play
import
role
interf
express
rhinoviru
receptor
intercellular
adhes
lowdens
lipoprotein
receptor
inflammatori
cytokin
interleukin
il
tumor
necrosi
factor
interferon
beta
tolllik
receptor
result
diminish
symptom
induc
hrv
global
effort
reduc
level
synthet
drug
justifi
studi
p
lactiflora
rootderiv
materi
potenti
antihrv
product
lead
molecul
prevent
treatment
hrv
human
rhinovirus
hrv
picornavirida
common
caus
upper
respiratori
tract
infect
common
cold
respons
half
case
common
cold
also
associ
sever
diseas
acut
otiti
media
children
sinus
adult
hrv
also
caus
sever
lower
respiratori
tract
symptom
pneumonia
wheez
bronchiol
exacerb
asthma
chronic
obstruct
pulmonari
diseas
infant
children
well
fatal
pneumonia
elderli
immunocompromis
adult
although
hrvinduc
upper
respiratori
ill
often
mild
selflimit
socioeconom
burden
caus
medic
visit
miss
school
work
hrv
infect
enorm
degre
drug
misus
abus
signific
antihistamin
antibiot
usag
caus
mani
side
effect
attempt
develop
effect
treatment
vaccin
rel
limit
unsuccess
serotyp
hrv
need
develop
select
antivir
agent
novel
target
site
establish
effect
hrv
manag
strategi
tactic
current
effect
antivir
therapi
approv
either
prevent
treatment
diseas
caus
hrv
infect
plant
may
provid
potenti
sourc
antivir
product
larg
constitut
potenti
sourc
bioactiv
secondari
metabolit
perceiv
gener
public
rel
safe
minim
impact
human
health
often
act
multipl
novel
target
site
certain
plant
prepar
constitu
regard
potenti
sourc
commerci
antivir
product
prevent
treatment
hrv
infect
previou
studi
shown
methanol
extract
root
chines
peoni
paeonia
lactiflora
palla
paeoniacea
possess
good
antivir
activ
toward
work
obtain
concern
potenti
use
p
lactiflora
manag
hrv
although
histor
p
lactiflora
root
g
dri
timesday
use
analges
hemostypt
bacteriostat
agent
aim
studi
assess
cytotox
antivir
effect
two
cell
line
hela
two
hrv
serotyp
paeonol
pa
gallic
acid
ga
pgg
p
lactiflora
root
use
tetrazolium
bromid
mtt
assay
antivir
activ
materi
compar
ribavirin
broadspectrum
antivir
agent
current
use
clinic
treat
variou
dna
rna
viru
infect
antivir
properti
mechan
action
constitu
also
elucid
use
realtim
quantit
revers
transcript
polymeras
chain
reaction
qrtpcr
sybr
green
dye
specif
enzymelink
immunosorb
assay
elisa
instrument
analysi
merck
silica
gel
f
plate
rptlc
agil
seri
highperform
liquid
chromatograph
hplc
santa
clara
ca
use
isol
activ
principl
ribavirin
puriti
mtt
purchas
tokyo
chemic
industri
tokyo
japan
sigmaaldrich
st
loui
mo
respect
anitbioticantimycot
minimum
essenti
medium
mem
purchas
invitrogen
grand
island
ny
fetal
bovin
serum
fb
suppli
paa
laboratori
etobicok
ontario
canada
protein
molecular
weight
standard
precis
plu
protein
blue
standard
purchas
biorad
life
scienc
hercul
ca
ripa
buffer
mammalian
cell
proteas
inhibitor
cocktail
purchas
sigmaaldrich
primari
antibodi
use
studi
follow
antibodi
rabbit
polyclon
intercellular
adhes
antilowdens
lipoprotein
receptor
ldlr
antibodi
rabbit
polyclon
ldlr
antiactin
antibodi
rabbit
polyclon
actin
purchas
abcam
cambridg
uk
secondari
antibodi
horseradish
peroxidas
conjug
goat
polyclon
rabbit
suppli
abcam
chemic
reagent
use
studi
analyt
grade
qualiti
avail
commerci
hela
atcc
human
epitheli
adenocarcinoma
cervix
cell
line
atcc
human
lung
fibroblast
cell
line
purchas
american
type
cultur
collect
atcc
manassa
va
cell
line
maintain
mem
supplement
fb
antibioticantimycot
solut
unitsl
penicillin
mgl
streptomycin
amphotericin
humidifi
incub
co
atcc
atcc
purchas
atcc
viru
titer
determin
cytopath
effect
cpe
hela
cell
express
tissu
cultur
infect
dose
tcid
per
ml
describ
previous
morgan
extract
procedur
airdri
root
p
lactiflora
perform
describ
previous
ngan
et
al
isol
activ
principl
viral
cpe
inhibit
assay
toward
hela
cell
use
hexanesolubl
fraction
biolog
activ
tabl
chromatograph
describ
previous
final
activ
principl
mg
isol
retent
time
min
activ
ethyl
acetatesolubl
fraction
g
chromatograph
cm
silica
gel
column
g
elut
gradient
chloroform
methanol
l
fig
spectroscop
analys
includ
ms
nmr
pa
compound
isol
antibacteri
principl
p
lactiflora
root
previou
work
spectral
data
compound
larg
ident
publish
data
ga
identifi
basi
follow
evid
white
powder
pgg
compound
isol
antibacteri
principl
p
lactiflora
root
previou
work
spectral
data
compound
larg
ident
publish
data
cytotox
test
materi
two
human
cell
line
evalu
use
mtt
assay
describ
previous
morgan
brief
stock
solut
mtt
prepar
ad
mgml
mtt
phosphatebuff
salin
pb
ph
stock
solut
sterilefilt
store
hela
cell
seed
onto
cultur
plate
densiti
cell
per
well
day
cultur
medium
remov
plate
monolay
cell
replac
media
contain
sever
differ
concentr
test
materi
dimethylsulfoxid
dmso
incub
co
day
cultur
plate
wash
pb
volum
medium
contain
mtt
ad
well
incub
h
condit
mtt
solut
remov
dmso
ad
well
final
plate
shaken
min
dissolv
purpl
formazan
crystal
form
absorb
read
nm
use
versamax
micropl
reader
molecular
devic
sunnyval
ca
refer
absorb
nm
monolay
hela
cell
seed
onto
cultur
plate
state
previous
subsequ
media
contain
sever
differ
concentr
test
materi
dmso
put
well
viru
stock
ad
produc
appropri
cpe
within
day
infect
ribavirin
serv
refer
control
similarli
prepar
neg
control
consist
dmso
solut
viral
inhibit
rate
vir
calcul
accord
formula
vir
tv
cv
cd
cv
tv
optic
densiti
measur
given
concentr
test
compound
hrv
infect
cell
cv
optic
densiti
measur
control
untreat
hrv
infect
cell
cd
optic
densiti
measur
control
untreat
hrv
uninfect
cell
viru
titer
infect
cultur
treat
pa
pgg
measur
tcid
use
mttbase
titrat
method
brief
cell
seed
cellsml
plate
h
cell
monolay
treat
pa
pgg
infect
concentr
ml
uninfect
untreat
infect
untreat
cultur
includ
assay
ribavirin
use
refer
control
h
incub
cultur
frozen
thaw
cell
debri
remov
centrifug
rpm
viru
supernat
collect
viru
titrat
perform
hela
cell
cultur
initi
dilut
supernat
prepar
follow
serial
ad
hela
cell
monolay
h
cell
mortal
measur
use
mtt
assay
state
previous
graph
built
plot
dead
cell
percentag
toward
viru
dilut
factor
viru
supernat
infect
point
calcul
linear
regress
analysi
curv
effect
test
compound
infect
particl
elucid
describ
previous
choi
et
al
approxim
quantiti
ic
valu
test
compound
appli
preincub
pa
pgg
ribavirin
h
monolay
cell
infect
pretreat
untreat
h
unbound
viru
remov
wash
well
pb
twice
cell
incub
fresh
medium
supplement
without
test
compound
day
mtt
test
antivir
activ
carri
state
previous
timeofaddit
effect
compound
examin
accord
method
choi
et
al
brief
monolay
cell
seed
onto
cultur
plate
state
previous
wash
pb
pa
pgg
ribavirin
separ
ad
onto
cell
either
h
h
h
infect
day
mtt
test
antivir
activ
carri
state
previous
evalu
level
gene
express
realtim
qrtpcr
sybr
green
dye
carri
infect
noninfect
cultur
monolay
grown
cm
cell
cultur
flask
corn
ny
treat
pa
pgg
incub
co
day
total
rna
extract
cultur
cell
use
rneasi
plu
mini
kit
qiagen
hilden
germani
accord
manufactur
instruct
contamin
genom
dna
remov
use
rnasefre
dnase
promega
madison
wi
complementari
dna
cdna
synthes
use
total
rna
revers
transcript
reaction
use
superscript
firststrand
synthesi
kit
invitrogen
carlsbad
ca
five
dilut
cdna
rna
perform
determin
pcr
effici
pg
per
reaction
qrtpcr
perform
plate
use
steponeplu
realtim
pcr
system
appli
biosystem
foster
ca
reaction
mixtur
consist
maxima
sybr
greenrox
qpcr
master
mix
thermo
scientif
foster
ca
forward
revers
primer
pmol
cdna
ng
doubledistil
water
final
volum
oligonucleotid
pcr
primer
pair
list
tabl
cell
lysat
infect
noninfect
cultur
day
incub
without
test
compound
obtain
ripa
buffer
mammalian
cell
proteas
inhibitor
cocktail
accord
manufactur
instruct
work
dilut
primari
antibodi
dilult
time
antildlr
antiactin
antibodi
respect
work
dilut
secondari
antibodi
antildlr
antiactin
respect
ten
microgram
cell
lysat
differ
treatment
mix
equal
volum
laemmli
sampl
buffer
boil
min
resolv
electrophoresi
sodium
dodecyl
sulfatepolyacrylamid
gel
sdspage
electrophoresi
v
h
protein
gel
transfer
onto
polyvinyl
difluorid
membran
pall
corpor
pensacola
fl
use
electroblot
apparatu
biorad
hercul
ca
membran
antildlr
incub
block
solut
contain
nonfat
dri
milk
h
inhibit
nonspecif
bind
membran
incub
overnight
primari
antibodi
wash
pb
min
three
time
membran
incub
secondari
antibodi
h
wash
pb
contain
vv
pbst
four
time
min
membran
antiactin
incub
pb
block
solut
contain
bsa
overnight
inhibit
nonspecif
bind
incub
antiactin
antibodi
block
solut
h
wash
four
time
min
pbst
room
temperatur
incub
second
antibodi
final
membran
develop
ecl
chemiluminesc
reagent
amersham
bioscienc
buckinghamshir
uk
expos
cppu
xray
film
agfa
mortsel
belgium
differ
protein
express
quantifi
use
molecular
imag
gel
doc
xr
system
biorad
hercul
ca
normal
actin
express
membran
express
ldlr
examin
use
realtim
qrtpcr
western
blot
furthermor
concentr
solubl
cellfre
cultur
supernat
day
treatment
measur
use
elisa
kit
pierc
biotechnolog
rockford
il
accord
manufactur
instruct
sensit
assay
ngml
concentr
test
sampl
determin
od
valu
use
standard
curv
assay
concentr
tnf
cellfre
cultur
supernat
day
treatment
measur
use
specif
elisa
opteia
tnf
elisa
kit
bd
bioscienc
san
diego
ca
use
assay
sensit
elisa
assay
pgml
respect
concentr
tnf
test
sampl
determin
od
valu
use
standard
curv
assay
cytotox
express
cytotox
concentr
cc
compound
reduc
viabil
cell
control
fifti
percent
inhibitori
concentr
ic
defin
compound
concentr
requir
reduc
viral
cpe
control
cc
ic
valu
determin
use
graphpad
prism
softwar
program
graphpad
softwar
la
jolla
ca
ic
valu
serotyp
treatment
consid
significantli
differ
one
anoth
confid
limit
cl
overlap
select
index
si
determin
ratio
cc
ic
data
repres
mean
sd
duplic
triplic
sampl
three
independ
experi
statist
analys
carri
use
sa
program
sa
institut
cari
nc
data
two
group
analyz
student
ttest
multipl
group
analyz
oneway
analysi
varianc
bonferroni
multipl
comparison
posttest
antivir
activ
pgg
ga
pa
toward
hela
cell
compar
ribavirin
use
mtt
assay
tabl
base
ic
effect
pa
pgg
hrv
titer
compar
ribavirin
tabl
due
antivir
activ
high
select
effect
pa
pgg
infect
particl
likewis
compar
ribavirin
fig
inhibit
rate
preincub
pa
pgg
ribavirin
respect
continu
presenc
pa
pgg
ribavirin
infect
led
signific
increas
inhibit
rate
investig
mode
action
pa
pgg
ribavirin
timeofaddit
experi
perform
fig
treatment
pa
pgg
consider
suppress
infect
ad
viru
inocul
h
inhibit
inhibit
compound
declin
less
ad
either
prior
h
post
h
infect
similar
result
observ
ml
ribavirin
evid
inhibitori
effect
pa
pgg
hrv
replic
cell
provid
realtim
qrtpcr
analysi
fig
presenc
pa
pgg
cell
cultur
infect
rna
replic
level
reduc
fold
respect
compar
level
cell
cultur
without
compound
fig
similarli
replic
level
cell
cultur
treat
pa
pgg
also
reduc
fold
respect
compar
untreat
cultur
fig
unbound
virus
remov
wash
phosphatebuff
salin
twice
cell
incub
fresh
medium
without
test
compound
day
inhibit
evalu
tetrazolium
method
express
inhibit
rate
bar
repres
mean
sd
triplic
sampl
three
independ
experi
p
use
student
ttest
effect
ldlr
express
mrna
express
day
hrv
infect
presenc
pa
pgg
investig
use
realtim
qrtpcr
fig
infect
increas
mrna
express
increas
reduc
addit
pa
pgg
furthermor
mrna
express
level
group
pgg
pa
treatment
lower
group
without
treatment
test
compound
mrna
express
ldlr
likewis
assess
fig
b
ldlr
mrna
express
infect
untreat
cell
similar
mock
untreat
cell
express
decreas
group
pa
pgg
treatment
use
elisa
fig
found
level
supernat
infect
cultur
higher
supernat
noninfect
cultur
level
supernat
cultur
treat
pa
pgg
significantli
lower
cultur
without
treatment
test
compound
howev
differ
level
mock
cultur
without
constitu
western
blot
analysi
ldlr
express
cell
day
hrv
infect
presenc
pa
pgg
perform
protein
level
noninfect
cultur
similar
cultur
infect
protein
level
cultur
treat
pa
pgg
test
concentr
also
similar
cultur
without
treatment
test
compound
fig
fig
presenc
pgg
cultur
result
sharp
declin
ldlr
protein
express
compar
cultur
without
pgg
treatment
regardless
infect
howev
pa
effect
express
ldlr
protein
fig
similar
result
also
observ
fig
effect
express
cytokin
mrna
express
variou
cytokin
day
infect
presenc
pa
pgg
assess
use
realtim
qrtpcr
evok
signific
increas
mrna
express
level
nontreat
cell
cultur
express
level
significantli
reduc
cell
cultur
treat
pa
pgg
although
differ
mrna
level
mock
cultur
without
constitu
fig
similar
result
also
observ
mrna
fig
express
tnf
mrna
cultur
challeng
similar
noninfect
cell
cultur
treatment
pa
pgg
remark
reduc
tnf
mrna
express
compar
untreat
cell
fig
although
mrna
express
occur
noninfect
cell
cultur
mrna
express
cell
cultur
infect
mrna
express
meaning
inhibit
pa
pgg
treatment
fig
mrna
express
also
highli
induc
induct
disappear
significantli
reduc
pa
pgg
treatment
fig
concentr
detect
elisa
infect
cell
supernat
significantli
higher
noninfect
cell
supernat
concentr
mock
cultur
treat
pa
higher
mock
cultur
without
treatment
howev
concentr
infect
cultur
reduc
treatment
pa
pgg
decreas
hrvinduc
secret
pgg
treatment
higher
pa
treatment
pa
pgg
affect
protein
express
concentrationdepend
manner
fig
similar
result
observ
fig
howev
tnf
protein
detect
supernat
cultur
data
shown
effect
mrna
express
mrna
express
infect
cell
increas
compar
uninfect
cell
fig
mrna
express
cultur
treat
pa
pgg
significantli
lower
cultur
without
treatment
test
compound
mani
plant
constitu
phenol
terpenoid
alkaloid
manifest
antivir
activ
toward
differ
virus
propos
altern
convent
antivir
drug
antihrv
constitu
deriv
plant
includ
alkaloid
eg
arborinin
ribalinin
ic
glaucin
ic
gallic
acid
ic
report
hrv
capsidbind
compound
toward
hrv
serotyp
show
exist
group
b
base
wide
rang
suscept
antivir
compound
current
studi
antivir
principl
p
lactiflora
root
determin
aryl
keton
pa
simpl
benzoic
acid
ga
glucohexos
pgg
constitu
exhibit
antivir
activ
toward
group
group
b
ic
pgg
ga
pa
toward
two
hrv
respect
although
ic
natur
compound
state
previous
pgg
exhibit
greater
antivir
activ
ribavirin
ic
toward
two
hrv
high
select
viru
titrat
assay
result
also
prove
constitu
antivir
activ
toward
hrv
origin
find
indic
materi
deriv
p
lactiflora
root
hold
promis
develop
novel
effect
natur
occur
antivir
agent
two
differ
hrv
group
b
pgg
report
possess
antivir
activ
toward
hepat
b
viru
influenza
viru
investig
mode
action
natur
antivir
may
contribut
develop
select
hrv
therapeut
altern
novel
target
site
mode
antivir
action
plant
secondari
substanc
well
document
rolling
schmidtk
kitazato
et
al
target
viru
molecul
like
specif
less
toxic
narrow
spectrum
virus
higher
risk
creat
resist
virus
contrari
chemic
target
cellular
molecul
may
possess
broader
antivir
activ
spectrum
less
risk
develop
viru
resist
may
toxic
host
cell
current
studi
pgg
pa
interact
particl
preexposur
viru
constitu
alter
infect
particl
base
timecours
test
pgg
pa
inhibit
infect
ad
viru
inocul
h
h
later
find
suggest
pgg
pa
may
interact
human
cell
earli
stage
hrv
infect
protect
cell
viru
destruct
mechan
action
constitu
cellular
protect
toward
still
remain
unclear
although
ribavirin
report
enter
host
cell
nucleosid
transport
sever
studi
addit
realtim
rtpcr
analysi
reveal
rna
replic
level
hrv
remark
reduc
cultur
treat
constitu
find
suggest
pgg
pa
may
block
reduc
entri
virus
cell
earli
stage
hrv
infect
protect
cell
viru
destruct
abat
viru
replic
detail
test
need
fulli
understand
mode
action
constitu
suggest
mode
antihrv
action
gallic
acid
might
deriv
inhibit
viru
absorpt
interfer
specif
virushost
cell
receptor
interact
one
potenti
intervent
antivir
chemotherapi
hrv
classifi
major
minor
group
base
bind
member
ldlr
famili
respect
critic
targetdock
molecul
epitheli
cell
hrv
serotyp
major
group
use
mechan
gain
entri
host
cell
suggest
antagon
virusreceptor
interact
would
appear
effect
way
inhibit
broad
spectrum
hrv
macrolid
antibiot
erythromycin
inhibit
infect
major
group
hrv
via
reduct
express
express
equal
induc
major
minor
group
hrv
hrvinduc
upregul
receptorrestrict
moreov
report
pretreat
sicam
alter
abil
induc
current
experi
demonstr
induc
form
express
elisa
result
reveal
protein
level
infect
cultur
treat
pa
pgg
significantli
lower
cultur
without
compound
treatment
although
differ
level
mock
cultur
without
constitu
howev
mrna
express
level
decreas
presenc
pgg
pa
infect
noninfect
cell
cultur
find
indic
constitu
interf
host
cell
protein
express
receptor
inhibit
receptor
rna
express
reduct
hrv
replic
addit
ldlr
mrna
express
also
reduc
presenc
pgg
pa
cultur
howev
ldlr
protein
express
inhibit
pgg
treatment
find
suggest
pgg
interfer
ldlr
express
inhibit
express
ldlr
rna
reduct
hrv
replic
wherea
pa
interf
ldlr
express
reduct
hrv
replic
pa
report
suppress
express
tnfstimul
human
umbil
vein
endotheli
cell
hrv
infect
induc
product
numer
compon
innat
immun
includ
imflamatori
mediat
kinin
leukotrien
histamin
interleukin
tnf
regul
activ
normal
cell
express
secret
surfaceexpress
report
import
function
respons
common
human
viral
infect
natur
host
cell
play
import
role
innat
immun
respons
toward
hrv
infect
replic
cycl
hrv
viral
doublestrand
rna
dsrna
recogn
interact
dsrna
activ
signal
cascad
trigger
increas
cytokin
product
host
cell
stimul
innat
immun
respons
suppos
inhibit
express
potenti
modulatori
effect
pathophysiolog
chang
relat
hrv
infect
cytokin
tnf
induc
upregul
express
adhes
molecul
epitheli
vascular
endotheli
cell
therebi
increas
cell
suscept
hrv
infect
concentr
nasal
secret
correl
sever
symptom
patient
cold
hrv
infect
report
respons
trigger
exacerb
asthma
induc
gene
express
cytokin
asthmat
subject
elisa
result
reveal
pa
induc
express
therefor
express
level
infect
cell
cultur
treat
pa
lower
infect
cell
cultur
without
constitu
consequ
hrv
replic
reduct
pgg
reduc
express
decreas
express
level
infect
cell
cultur
treat
pgg
result
interfer
constitu
host
cell
protein
express
hrv
replic
current
studi
also
indic
constitu
reduc
express
cytokin
tnf
result
diminish
symptom
induc
hrv
may
effect
constitu
block
reduc
entri
virus
cell
result
reduc
hrvrna
replic
play
import
role
interf
hrvinduc
gene
express
conclus
p
lactiflora
rootderiv
prepar
contain
pgg
pa
could
use
antivir
agent
prevent
treatment
hrv
infect
antivir
action
pgg
pa
may
indic
least
one
pharmacolog
action
p
lactiflora
practic
use
prepar
novel
antihrv
product
proceed
research
need
establish
safeti
respect
human
whether
activ
exert
vivo
consumpt
p
lactiflora
rootderiv
product
human
lastli
detail
test
need
understand
improv
antihrv
potenc
stabil
eventu
commerci
develop
